MEMPHIS, Tenn., Jan. 8 /PRNewswire/ -- Neurorecovery, Inc. (NRI), a biopharmaceutical company focused on treatments for peripheral neuropathies, announced that it will be presenting at the 25th Annual JP Morgan Healthcare Conference on Wednesday, January 10, 2007 at 4:30 p.m. pacific time in San Francisco, California.
James Terwilliger, NRI’s President will present a company overview and discuss its clinical development efforts.
About Neurorecovery Incorporated. NRI is a biopharmaceutical company focused on treatment for peripheral neuropathies. Our lead product, Ampydin (IR), is an immediate release version of 4-Aminopyridine, or 4-AP. 4- Aminopyridine is currently on the FDA’s compounding for compassionate use list for treatment of certain neuropathies and for spinal cord injury and MS. NRI is moving into a Phase III clinical trial with the proposed indication of 4- Aminopyridine for the treatment of chronic functional motor and sensory deficits resulting from Guillain-Barre Syndrome. The Phase IIa trial was partially funded by the National Institute of Disability, Rehab and Rehabilitation (NIDRR) and the Phase IIb trial was funded by a grant from the FDA Orphan Drug Office. We are a Delaware Corporation headquartered in Memphis, Tennessee.
Cautionary Note Regarding Forward-Looking Statements. This press release contains forward-looking statements that reflect Neurorecovery’s current expectations about its prospects and opportunities, including, without limitation, expectations regarding Ampydin (IR) and its other products. Neurorecovery has tried to identify these forward-looking statements by using words such as “plans,” “believes,” “expects,” “anticipates,” “will,” “should” or similar expressions, but these words are not the exclusive means for identifying such statements. Neurorecovery cautions that a number of risks, uncertainties, and other important factors could cause Neurorecovery’s actual results, performance or achievements to differ materially from those expressed in, or implied by, these forward-looking statements. Drug development and commercialization involves a high degree of risk including the risk of unfavorable results from future studies of Ampydin (IR), delays in obtaining or failure to obtain FDA approval of Ampydin (IR), the inability to obtain additional financing to support Neurorecovery’s operations, competition from the biotech and pharmaceutical industries, failure to protect its intellectual property or to defend against the intellectual property claims of others, and other unexpected events.
Neurorecovery undertakes no obligation to update or revise any forward- looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially and investors should not place undue reliance on these statements. Neurorecovery disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
http://www.neurorecoveryinc.com
Neurorecovery, Inc.
CONTACT: Ben Labry of Neurorecovery, Inc., +1-901-537-2992
Web site: http://www.neurorecoveryinc.com//
